sitafloxacin

Sitafloxacin is a new-generation, broad-spectrum oral fluoroquinolone antibiotic developed by Daiichi Sankyo. It is highly active against a wide range of Gram-positive, Gram-negative, and anaerobic bacteria, including strains resistant to other fluoroquinolones. Sitafloxacin acts by inhibiting bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for bacterial DNA replication, transcription, repair, and recombination. It is indicated for the treatment of various infections such as respiratory tract infections (including pneumonia), urinary tract infections (such as pyelonephritis and cystitis), odontogenic infections, otorhinolaryngological infections (e.g., otitis media and sinusitis), periodontitis, pericoronitis, oral infections, and as part of salvage therapy for Helicobacter pylori infection. Sitafloxacin was approved in Japan in 2008 and is also marketed in Thailand; its use outside Asia is limited due to the risk of phototoxicity in certain populations[4][5][6].

Brand names

Gracevit

Other names

sitafloxacin hydrate